Aligos Therapeutics Income Statement (2019-2026) | ALGS

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.54M1.54M0.37M2.57M3.54M2.58M4.29M2.15M3.82M0.69M1.06M1.25M0.61M0.31M0.96M0.74M0.17M2.83M
Operating items
Research & Development (Quarter)
24.55M28.13M28.60M31.68M16.51M17.79M19.10M18.14M16.78M15.87M22.26M16.37M21.10M16.77M16.03M14.50M13.98M23.94M17.04M23.35M
Selling, General & Administrative (Quarter)
6.56M6.47M9.72M6.45M7.58M5.26M7.12M8.51M9.25M6.44M6.42M6.67M6.38M4.63M5.16M5.05M5.56M5.17M4.95M6.41M
Other Operating Expenses (Quarter)
-0.23M0.07M0.18M-0.01M0.52M0.28M0.84M1.00M1.11M1.06M0.24M1.58M1.23M1.07M0.57M0.88M1.21M1.08M0.75M0.81M
Operating Expenses (Quarter)
31.11M34.60M38.31M38.13M24.09M23.05M26.22M26.64M26.03M22.31M28.68M23.03M27.48M21.40M21.19M19.55M19.53M29.10M21.98M29.76M
Operating Income (Quarter)
-29.57M-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M61.16M-26.93M
EBIT (Quarter)
-29.57M-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M61.16M-26.93M
Net income details
EBT (Quarter)
-29.79M-33.00M-37.77M-35.56M-19.88M-18.66M-21.84M-22.92M-18.03M-18.01M-27.92M-34.84M5.25M-19.17M-82.12M43.13M-15.68M-31.48M-19.85M-22.72M
Tax Provisions (Quarter)
0.03M0.13M-0.06M0.05M0.05M-0.04M0.05M0.04M0.76M0.03M-0.03M0.02M0.19M0.09M0.03M0.04M0.18M0.06M0.03M0.32M
Profit After Tax (Quarter)
-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M
Income from Continuing Operations (Quarter)
-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M
Consolidated Net Income (Quarter)
-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M
Income towards Parent Company (Quarter)
-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M
Net Income towards Common Stockholders (Quarter)
-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M
Additional items
EPS (Basic) (Quarter)
-0.79-0.78-0.91-0.84-0.47-0.44-0.51-0.53-0.43-10.370.39-5.580.81-3.07-13.105.12-1.53-3.04-2.01-2.21
EPS (Weighted Average and Diluted) (Quarter)
-0.78-0.84-0.47-0.44-0.51-0.53-0.43-10.370.39-5.580.81-3.07-13.10-2.11-1.53-3.04-2.01-2.21
Shares Outstanding (Weighted Average) (Quarter)
37.53M39.15M39.86M42.51M42.67M42.65M42.70M42.91M43.22M1.73M2.56M156.15M6.26M6.27M6.26M8.41M9.39M10.37M9.88M10.40M
Shares Outstanding (Diluted Average) (Quarter)
39.15M42.51M42.67M42.76M42.70M42.91M43.06M1.73M2.56M156.15M156.30M6.26M6.26M8.71M9.72M9.88M10.40M
EBITDA (Quarter)
-29.84M-33.12M-37.01M-35.86M-20.08M-18.51M-21.64M-22.86M-18.79M-18.04M-27.84M-34.93M5.08M-19.18M-82.28M43.08M-15.89M-31.50M-19.87M-23.07M
Tax Rate (Quarter)
-0.09%-0.38%0.15%-0.15%-0.24%0.23%-0.22%-0.17%-4.20%-0.16%0.11%-0.07%3.60%-0.47%-0.03%0.10%-1.18%-0.18%-0.15%-1.40%